Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
12.16
+0.23 (1.93%)
Oct 9, 2026, 3:12 PM EDT - Market open
Biohaven Earnings Call Transcripts
Fiscal Year 2024
-
Troriluzole demonstrated a 50%-70% reduction in SCA progression over three years, with significant delays in disease decline and reduced fall risk, meeting all primary and secondary endpoints. The therapy was safe, well-tolerated, and is poised for FDA and EMA submissions, potentially becoming the first approved treatment for SCA.